Almirall gets in on the eczema actionSanofi’s Dupixent has shown there is a market for biologic drugs to treat eczema, and now Spain’s Almirall Share XAlmirall gets in on the eczema actionhttps://pharmaphorum.com/views-analysis-market-access/almirall-gets-in-on-the-eczema-action/
Almirall takes option on Dermira’s eczema drug lebrikizumabSpain’s Almirall has taken an option granting rights to develop and market Dermira’s eczema drug lebrikizumab in Europe, Share XAlmirall takes option on Dermira’s eczema drug lebrikizumabhttps://pharmaphorum.com/news/almirall-takes-option-on-dermiras-eczema-drug-lebrikizumab/
Almirall signs atopic dermatitis R&D deal with HitgenAlmirall has signed a new research collaboration with Chinese biotech HitGen, to find potential new oral therapies for Share XAlmirall signs atopic dermatitis R&D deal with Hitgenhttps://pharmaphorum.com/news/almirall-signs-atopic-dermatitis-rd-deal-with-hitgen/
NICE okays UCB’s Cimzia, nixes Almirall’s Ilumetri, in psoriasisNICE has recommended in draft guidance that UCB’s Cimzia can receive regular NHS funding for plaque psoriasis, but Share XNICE okays UCB’s Cimzia, nixes Almirall’s Ilumetri, in psoriasishttps://pharmaphorum.com/news/nice-okays-ucbs-cimzia-nixes-almirall-ilumetri-in-psoriasis/
Almirall buys Allergan’s derma portfolioAlmirall is expanding its business by buying Allergan’s dermatology portfolio. The Spanish pharma company will buy five brands Share XAlmirall buys Allergan’s derma portfoliohttps://pharmaphorum.com/news/almirall-buys-allergans-derma-portfolio/
